Oppenheimer & Co. Inc released a research report on HCA Holdings Inc. HCA providing more clarity around operational trends and reiterating its Outperform rating.
In the report, Oppenheimer & Co. writes, “HCA reported strong y-y revenue and volume growth for the two months ended Aug 31. The decline in Medicare revenues in 2Q was driven by a shift in the case mix, primarily from declines in cardiovascular surgeries ($28M, $25M of which is expected to recur in future quarters). Overall, HCA provided additional clarity that should help the market further understand the issues faced during 2Q.”
Oppenheimer & Co. Inc has an Outperform rating and a $37.00 price target on HCA Holdings Inc., which closed yesterday at $18.40.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in